Musa K. Oladejo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Musa K. Oladejo has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Aminah Bello
School of Biosciences, Faculty of Health and Medical Sciences, Taylor’s University , Subang Jaya, Selangor 47500
2 shared publications - Gbadebo Maroof Oyeniyi
University of Ilorin, Nigeria
2 shared publications - Hassanat T. Fayemo
Department of Biochemistry, Faculty of Life Sciences University of Ilorin Ilorin Nigeria
2 shared publications - Kamoru Ademola Adedokun
Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
2 shared publications - Tajudeen A. Adebisi
NMC Healthcare, Medical Record and Clinical Documentation Unit , Abu Dhabi 764659, UAE
2 shared publications - Uchechukwu Brian Eziagu
Department of Histopathology, University of Uyo Teaching Hospital, Uyo, Akwa Ibom State, Nigeria
2 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 220 (1)
Exosomal nanocarriers of immune fate: molecular insights into cancer immunity, pathogen defense, and emerging immunotherapies
Exosomes, the nanoscale extracellular vesicles released by most cell types, are increasingly recognized as potent regulators of immune communication. This review provides a mechanistic and integrative perspective on the immunological functions of exosomes, highlighting their roles in both immune stimulation and suppression across physiological and pathological contexts. We begin by dissecting the molecular architecture of exosomes—focusing on immunologically active components such as ESCRT proteins, tetraspanins, RabGTPases, and lipid mediators—and explore how these elements contribute to exosome biogenesis and immune function. The review further examines exosomal cargo enriched in pattern recognition receptor (PRR) ligands, including damage-associated molecular patterns (DAMPs), pathogen-associated molecular patterns (PAMPs), and microRNAs, and discusses how these molecules activate toll-like receptors and other PRRs to orchestrate innate immune responses through endosomal and cytosolic signaling cascades. Special emphasis is given to MHC-mediated antigen presentation via exosomes, distinguishing classical and non-canonical pathways and their interplay with downstream immune signaling mechanisms. We present a dichotomous view of exosomes as both immunostimulatory and immunosuppressive agents, detailing their roles in T-cell cross-priming, dendritic cell maturation, tumor progression, and metastasis. Moreover, we review pathogen-driven hijacking of exosomal pathways and their implications for immune evasion. Finally, we discuss the therapeutic promise of exosomes in cancer immunotherapy and vaccine design, advocating for their strategic integration into next-generation immunomodulatory approaches.
- 6 January 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 220 (1)
Open AccessExosomal nanocarriers of immune fate: molecular insights into cancer immunity, pathogen defense, and emerging immunotherapies
Exosomes, the nanoscale extracellular vesicles released by most cell types, are increasingly recognized as potent regulators of immune communication. This review provides a mechanistic and integrative perspective on the immunological functions of exosomes, highlighting their roles in both immune stimulation and suppression across physiological and pathological contexts. We begin by dissecting the molecular architecture of exosomes—focusing on immunologically active components such as ESCRT proteins, tetraspanins, RabGTPases, and lipid mediators—and explore how these elements contribute to exosome biogenesis and immune function. The review further examines exosomal cargo enriched in pattern recognition receptor (PRR) ligands, including damage-associated molecular patterns (DAMPs), pathogen-associated molecular patterns (PAMPs), and microRNAs, and discusses how these molecules activate toll-like receptors and other PRRs to orchestrate innate immune responses through endosomal and cytosolic signaling cascades. Special emphasis is given to MHC-mediated antigen presentation via exosomes, distinguishing classical and non-canonical pathways and their interplay with downstream immune signaling mechanisms. We present a dichotomous view of exosomes as both immunostimulatory and immunosuppressive agents, detailing their roles in T-cell cross-priming, dendritic cell maturation, tumor progression, and metastasis. Moreover, we review pathogen-driven hijacking of exosomal pathways and their implications for immune evasion. Finally, we discuss the therapeutic promise of exosomes in cancer immunotherapy and vaccine design, advocating for their strategic integration into next-generation immunomodulatory approaches.
- 21 November 2025
- Published by Wiley in HIV Medicine
- Vol. 27 (2) , 234-246
HIV / AIDS in transition: Global disparities, Africa's uneven progress and struggles, and the emerging threat of funding cuts (global burden of disease study, 1990–2021)
Background: HIV/AIDS remains a global health crisis marked by profound regional disparities. Sub‐Saharan Africa (SSA) bears the greatest burden but has achieved partial progress in reducing its impact. Within the region, however, heterogeneous patterns of progress and setbacks persist, underscoring ongoing challenges in epidemic control and suggesting potential misalignment in the focus of current interventions. Methods: We analysed HIV/AIDS disability‐adjusted life years (DALYs) from 2016 to 2021, disaggregated at subregional and local levels across continents using Global Burden of Disease (GBD) estimates. This high‐resolution analytical approach enabled the identification of nuanced temporal trends and geographic hotspots requiring urgent intervention, with particular emphasis on SSA. Findings: Southern SSA recorded a 20.8% decline in DALY rates, from 18 280 to 14 470 per 100 000 population, while eastern, western and central SSA each achieved reductions exceeding 27%. Despite these gains, some areas maintained alarmingly high burdens, including Lesotho (26 516), eastern Cape, South Africa (25 004), Eswatini (22 944) and Homa Bay, Kenya (21 747). Outside Africa, the Caribbean achieved a 29% decline, whereas North America and Europe registered more modest improvements. In Asia, several Indian states recorded up to 27% reductions, contrasted by increases in parts of Pakistan, Mongolia, China and Yemen. Interpretation: Marked regional contrasts highlight the need to reframe HIV/AIDS control strategies at the subregional level. Despite setbacks linked to the COVID‐19 pandemic, targeted, data‐driven interventions in persistent high‐burden areas remain essential to sustain progress and accelerate the global HIV/AIDS response. Yet, just as encouraging transitions are beginning to take hold across several parts of SSA, the continent is now confronted—suddenly and unprepared—for a renewed challenge: a decline in HIV/AIDS funding.
- 21 November 2025
- Published by Wiley in HIV Medicine
- Vol. 27 (2) , 234-246
HIV / AIDS in transition: Global disparities, Africa's uneven progress and struggles, and the emerging threat of funding cuts (global burden of disease study, 1990–2021)
Background: HIV/AIDS remains a global health crisis marked by profound regional disparities. Sub‐Saharan Africa (SSA) bears the greatest burden but has achieved partial progress in reducing its impact. Within the region, however, heterogeneous patterns of progress and setbacks persist, underscoring ongoing challenges in epidemic control and suggesting potential misalignment in the focus of current interventions. Methods: We analysed HIV/AIDS disability‐adjusted life years (DALYs) from 2016 to 2021, disaggregated at subregional and local levels across continents using Global Burden of Disease (GBD) estimates. This high‐resolution analytical approach enabled the identification of nuanced temporal trends and geographic hotspots requiring urgent intervention, with particular emphasis on SSA. Findings: Southern SSA recorded a 20.8% decline in DALY rates, from 18 280 to 14 470 per 100 000 population, while eastern, western and central SSA each achieved reductions exceeding 27%. Despite these gains, some areas maintained alarmingly high burdens, including Lesotho (26 516), eastern Cape, South Africa (25 004), Eswatini (22 944) and Homa Bay, Kenya (21 747). Outside Africa, the Caribbean achieved a 29% decline, whereas North America and Europe registered more modest improvements. In Asia, several Indian states recorded up to 27% reductions, contrasted by increases in parts of Pakistan, Mongolia, China and Yemen. Interpretation: Marked regional contrasts highlight the need to reframe HIV/AIDS control strategies at the subregional level. Despite setbacks linked to the COVID‐19 pandemic, targeted, data‐driven interventions in persistent high‐burden areas remain essential to sustain progress and accelerate the global HIV/AIDS response. Yet, just as encouraging transitions are beginning to take hold across several parts of SSA, the continent is now confronted—suddenly and unprepared—for a renewed challenge: a decline in HIV/AIDS funding.
- Open Access
- 23 August 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (9) , 1250
Bioactivity-Guided Fractionation and Mechanistic Insights into Aristolochia ringens Root Extract-Induced G1 Phase Arrest and Mitochondria-Mediated Apoptosis in Human Colon Adenocarcinoma Cells
Background/Objectives: Aristolochia ringens, a medicinal plant widely used in traditional medicine, has shown potential therapeutic applications. This study aimed to investigate the anticancer mechanism of action of its crude extract against human colorectal adenocarcinoma cells (Caco-2 and HT-29). Methods: Cell viability was assessed using the MTT assay to determine IC50 values. Immunofluorescence microscopy was used to examine nuclear morphology and microtubule integrity. Flow cytometry with PI staining was used for cell cycle analysis and Annexin V-FITC/PI staining for apoptosis detection. Mitochondrial membrane potential was evaluated using JC-1 dye. Bioactivity-guided fractionation was performed via HPLC, and GC–MS was used to profile active constituents. Results: The extract exhibited dose-dependent cytotoxicity with IC50 values below 30 µg/mL in colon adenocarcinoma cell lines. Treated Caco-2 cells showed nuclear shrinkage and disrupted microtubules. PI-based flow cytometry revealed G1 phase arrest, and Annexin V-FITC/PI staining indicated enhanced late apoptosis. JC-1 staining demonstrated mitochondrial depolarization. HPLC fractionation identified fractions 2 and 3 as active, and preliminary GC–MS analysis tentatively annotated the presence of alkaloids, sesquiterpenes/diterpenes, and steroidal compounds. Conclusions: A. ringens exerts anticancer effects through a mitochondria-mediated apoptotic pathway, involving G1 checkpoint arrest and cytoskeletal disruption. These findings provide the first integrated cellular and mechanistic evidence of its anticancer potential in colorectal cancer, supporting its promise as a source of novel therapeutic lead compounds.
- 23 August 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (9) , 1250
Open AccessBioactivity-Guided Fractionation and Mechanistic Insights into Aristolochia ringens Root Extract-Induced G1 Phase Arrest and Mitochondria-Mediated Apoptosis in Human Colon Adenocarcinoma Cells
Background/Objectives: Aristolochia ringens, a medicinal plant widely used in traditional medicine, has shown potential therapeutic applications. This study aimed to investigate the anticancer mechanism of action of its crude extract against human colorectal adenocarcinoma cells (Caco-2 and HT-29). Methods: Cell viability was assessed using the MTT assay to determine IC50 values. Immunofluorescence microscopy was used to examine nuclear morphology and microtubule integrity. Flow cytometry with PI staining was used for cell cycle analysis and Annexin V-FITC/PI staining for apoptosis detection. Mitochondrial membrane potential was evaluated using JC-1 dye. Bioactivity-guided fractionation was performed via HPLC, and GC–MS was used to profile active constituents. Results: The extract exhibited dose-dependent cytotoxicity with IC50 values below 30 µg/mL in colon adenocarcinoma cell lines. Treated Caco-2 cells showed nuclear shrinkage and disrupted microtubules. PI-based flow cytometry revealed G1 phase arrest, and Annexin V-FITC/PI staining indicated enhanced late apoptosis. JC-1 staining demonstrated mitochondrial depolarization. HPLC fractionation identified fractions 2 and 3 as active, and preliminary GC–MS analysis tentatively annotated the presence of alkaloids, sesquiterpenes/diterpenes, and steroidal compounds. Conclusions: A. ringens exerts anticancer effects through a mitochondria-mediated apoptotic pathway, involving G1 checkpoint arrest and cytoskeletal disruption. These findings provide the first integrated cellular and mechanistic evidence of its anticancer potential in colorectal cancer, supporting its promise as a source of novel therapeutic lead compounds.